medigraphic.com

2019, Number 2

<< Back Next >>

Rev Clin Esc Med 2019; 9 (2)

Pseudomixoma peritonei, una revisión bibliográfica actualizada

Chaves CA, Bolaños MI, Mora MK, Gallón VL, Ibañez MM, López BH, Alvarado DP

Language: Spanish
References: 44
Page: 96-104
PDF size: 513.45 Kb.


ABSTRACT

Pseudomyxoma peritonei (PMP) is a condition characterized by progressive accumulation of mucinous ascites and implantation of mucinous tumors in the peritoneal cavity. This article is a bibliographic review in which 44 bibliographical sources were used. From the information collected, we can say that the PMP is a rare disease, which has the epithelial neoplasms of the appendix as its main etiology. Its clinic is classically presented with vague abdominal symptoms. The most used diagnostic method is CT. Its treatment is based on surgical resection together with intraperitoneal chemotherapy (HIPEC), a method that has shown, in recent years, to increase survival compared to traditional therapy (only surgical resection). However, the research studies carried out so far have been with small populations, of a retrospective type and are not multicentric, for which reason there is not enough evidence to support the definitive management for this pathology.


REFERENCES

  1. Weaver CH. Mucocele of the appendix with mucinous degeneration. Am J Surg. 1937; 36 (2):523- 526

  2. Werth. Klinische und anatomische Untersuchungen zur Lehre von den Bauchgeschwülsten und der Laparatomie. Arch Für Gynäkol. 1884;24(1):100– 118.

  3. Frankel E. Uher das sogenanute pseudomyxoma peritonei. Med Wochenschr 1901;48: 965–970

  4. Amini A Masoumi-Moghaddam S Ehteda A Morris D. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet Journal of Rare Diseases, 2014; 9-71.

  5. Baratti D Kusamura S Milione M et al. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. Ann Surg Oncol. 2016;23(13):4222–4230.

  6. Prat J. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Adv Anat Pathol. 1999;6:247-274.

  7. Buell-Gutbrod R Gwin K. Pathologic Diagnosis, Origin, and Natural History of Pseudomyxoma Peritonei. American Society of Clinical Oncology educational Book. 2013;33-221

  8. Moran BJ Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12(3):585– 603.

  9. Smeenk RM van Velthuysen ML Verwaal VJ Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201

  10. Dayal S Taflampas P Riss S et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum. 2013;56(12):1366– 1372.

  11. O’Connell JT Tomlinson JS Roberts AA McGonigle KF Barsky SH. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol. 2002;161:551–564.

  12. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219:109–111

  13. Mittal R Chandramohan A Moran B. Pseudomyxoma peritonei: natural history and treatment. International Journal of Hyperthermia. 2017;33(5) 511-519

  14. Pestieau SR Esquivel J Sugarbaker PH. Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome. Ann Surg Oncol. 2000;7(3):199-203

  15. Carr N Path FRC Cecil T et al. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia. Am J Surg Pathol. 2016;40:14–26

  16. Smeenk RM Verwaal VJ Zoetmulder FA. Pseudomyxoma peritonei. Cancer Treat Rev. 2007;33:138-145.

  17. Sulkin TVC O’Neill H Amin AI Moran B. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol. 2002;57(7):608–13.

  18. Jacquet P Jelinek JS Chang D Koslowe P Sugarbaker PH. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for y to reductive surgery. J Am Coll Surg. 1995;181(6):530–8

  19. Low RN Barone RM Gurney JM Muller WD. Mucinous appendiceal neoplasms: preoperative MR staging and classification compared with surgical and histopathologic findings. AJR Am J Roentgenol. 2008;190(3):656–665.

  20. Cotton F Pellet O Gilly FN Granier A Sournac L Glehen O. MRI evaluation of bulky tumor masses in the mesentery and bladder involvement in peritoneal carcinomatosis. Eur J Surg Oncol. 2006 Dec;32(10):1212–1216.

  21. Low RN Sebrechts CP Barone RM Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. AJR Am J Roentgenol. 2009;193(2):461–470.

  22. Carmignani CP Hampton R Sugarbaker CE Chang D Sugarbaker PH: Utility of CEA and CA 19–9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 2004;87:162–166.

  23. van Ruth S Hart AA Bonfrer JM Verwaal VJ Zoetmulder FA. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2002;9:961-967

  24. Koh JL Liauw W Chua T Morris DL. Carbohydrate antigen 19–9 (CA 19–9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Gastrointest Oncol. 2013;4:173–181.

  25. Smeenk RM Bruin SC van Velthuysen ML Verwaal VJ. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45:527–575.

  26. Pai RK Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classifıcation. Adv Anat Pathol. 2005;12:291-311.

  27. Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol. 2004;21:134-150.

  28. Järvinen P Järvinen HJ Lepisto A. Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis. 2010;12:868–872.

  29. Youssef H Newman C Chandrakumaran K Mohamed F Cecil TD Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54(3):293–9.

  30. Sugarbaker PH Chang D Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–31.

  31. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27(3), 239–243

  32. Sugarbaker PH Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:362-369

  33. Chua TC Moran BJ, Sugarbaker PH et al. Earlyand long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-2456.

  34. Rizvi SA Syed W Shergill R. Approach to pseudomyxoma peritonei. World Journal of Gastrointestinal Surgery. 2018;10(5):49-56

  35. Chua TC Yan TD Saxena A Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900-907

  36. Rubino MS Abdel-Misih RZ Bennett JJ et al. Peritoneal surface malignancies and regional treatment: a review of the literature. Surg Oncol. 2012;21:87-94.

  37. Sugarbaker PH. New standard of care for appendiceal epitelial neoplasms and pseudomyxoma peritonei syndrome. Lancet Oncol. 2006;7:69-76

  38. Baratti D Kusamura S Milione M Bruno F Guaglio M Deraco M. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2018;25:404-413.

  39. Pallas N Karamveri C Kyziridis D et al. Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis. J BUON. 2017;22:1547-1553.

  40. Chia CS Seshadri RA Kepenekian V Vaudoyer D Passot G Glehen O. Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. Pleura and Peritoneum. 2016;1:65-77

  41. Moran B Cecil T Chandrakumaran K Arnold S Mohamed F Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis. 2015;17:772- 778

  42. Gupta A Chandrakumaran K Cecil TD Mohamed F Moran BJ. Tumour grade and complete tumour removal affects survival after cytoreductive surgery and HIPEC for Pseudomyxoma Peritonei (PMP) of appendiceal origin. PMI Basingstoke. 2014. Disponible en: https://www.acpgbi.org.uk/content/ uploads/2015/11/SP016-Colorectal-Cancer-Gupta- Tripartite-2014.pdf.

  43. Smeenk RM Verwaal VJ Antonini N Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104-109.

  44. Chua TC Moran BJ Sugarbaker PH et al. Earlyand long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012 Jul 10;30(20):2449–56




2020     |     www.medigraphic.com